During a Targeted Oncology™ Case-Based Roundtable™ event, Surbhi Sidana, MD, discussed with participants how they use quadruplet or triplet frontline regimens for patients with transplant-eligible multiple myeloma. This is the first of 2 articles based on this event.
DISCUSSION QUESTIONS
SURBHI SIDANA, MD: Especially with neutropenia and other AEs, have you noticed a difference in the AEs or is the tolerability comparable when you use a quadruplet versus a triplet?
VEENA CHARU, MD: I have seen a bit more neutropenia [with quadruplet], but otherwise it’s very well handled.
SIDANA: Did you have to use G-CSF [granulocyte-colony stimulating factor] at that time? Did you elect to observe, change the dose, or delay the dose?
CHARU: I elected to observe and delayed the treatment a little bit.
SIDANA: Did this patient have recurrent infections or asymptomatic neutropenia?
CHARU: [Neutropenia was] asymptomatic in this patient.
SIDANA: Are there any other thoughts in terms of AEs or your experience using a quadruplet versus triplet?
SAM YEH, MD: If they’re getting infection and pneumonia, do you check the IgG [immunoglobulin G] level?
SIDANA: We always check IgG levels because we’re following immunoglobulins, but I don’t replace them in the newly diagnosed setting if they are at 300 mg/dL but they don’t have any infections. But, if they start getting recurrent infections, especially sinopulmonary infections…for sure I’m replacing the IgG with IVIG [intravenous immunoglobulin]. Is that your practice, too, Dr Yeh?
YEH: Yes.
SIDANA: I think I’m using a lot of IVIG because I use CAR [chimeric antigen receptor] T-cell therapy, [autologous stem cell] transplant, and bispecifics [in general]. But for these patients, I’m not using that much IVIG.
YEH: Yes, [I use it more frequently] in chronic lymphocytic leukemia than multiple myeloma.
SIDHARTH R. ANAND, MD: I had a question on the CAR T-cell therapy patients who get daratumumab [Darzalex]. Is there any impact on their CAR T-cell therapy efficacy or does that ever play a role if you’re considering CAR T-cell therapy in the future?
SIDANA: No, not at all. There are no data to suggest that. There are some intriguing data [on what will] activate different cells, [and ask] will that synergize? That is a different question, but there are no data to suggest any harm. A lot of our patients get daratumumab before CAR T-cell therapy.
YEH: Our institution seems to think isatuximab [Sarclisa] and daratumumab are interchangeable. What are your feelings about that?
SIDANA: There has never been a head-to-head [trial]. They both target CD38. They are just different epitopes. I think the answer is we don’t know, and some institutions might prefer one versus the other based on formulary [or] based on convenience. The one thing that is not there for isatuximab is the subcutaneous formulation, and sometimes patients have a strong preference one way or the other. But otherwise, I don’t think we can say that there is any difference between one or the other.
THOMAS SPILLANE, MD: For the older patient who is not a transplant candidate, are you still thinking of using the quadruplet regimen? In those patients, dexamethasone and lenalidomide [Revlimid] are some of the more toxic drugs and so dose reducing those [is needed].
SIDANA: The bottom line is mostly I’m using a triplet, but there are some very high-risk, borderline-fit patients whom you’ll [harm] with transplant but they’re otherwise fit and they’re very high risk, like [with] a 17p deletion. [Sometimes] I use a quadruplet combination. There is a niche section of patients who are not transplant eligible where I am using a quadruplet regimen. Have you used it in your transplant-ineligible patients?
SPILLANE: Yes, in a similar situation where they were maybe too old or had comorbid medical problems for transplant but I also felt like a quadruplet was appropriate. But I gave them small doses of lenalidomide, and smaller doses of dexamethasone, and relatively smaller doses of bortezomib [Velcade].
SIDANA: I think dexamethasone is key. No one talks about it too much anymore because it’s not a new drug, but I never give more than 20 mg [daily] of dexamethasone to my patients over 70 years old. I don’t think it’s going to benefit them at all.
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Tolerability Helps Decide Third-Line Treatment in Advanced RCC
April 30th 2024During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
Read More